Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

59.21 -0.01 (-0.02%)
Streaming Delayed Price Updated: 11:22 AM EST, Dec 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bristol-Myers Squibb

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >
The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen’s Commitment of $8 Million
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Present at J.P. Morgan’s 41st Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Dividend Increase
From Bristol Myers Squibb
Via Business Wire
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
From Bristol Myers Squibb
Via Business Wire
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:RCUS),(NASDAQ:AZN),(NYSE:BMY),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 14, 2022 – USA News Group – English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his... 
Via FinancialNewsMedia
Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022
From Bristol Myers Squibb
Via Business Wire
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up. 
Via TheNewswire.com
Exposures Product Safety
Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial
From Bristol Myers Squibb
Via Business Wire
MarketBeat: Week in Review 10/24-10/28
Stocks finished the week on a bullish note, and the MarketBeat analysts continue to guide you to the stocks and stories that are moving the market 
Via MarketBeat
Topics Economy Electric Vehicles
Exposures Economy Electric Vehicles Interest Rates
Strong Fundamentals Make Bristol Myers Squibb Stock a Real Value
Bristol Myers Squibb stock posts results that establish it as an attractive value stock, even if it may not be as undervalued as it appeared before. 
Via MarketBeat
New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
From Bristol Myers Squibb
Via Business Wire
The Robert A. Winn Diversity in Clinical Trials Award Program Announces the Second Group of Physicians to be Trained in the $114 Million Program
From Bristol Myers Squibb
Via Business Wire
New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period
From Bristol Myers Squibb
Via Business Wire
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma
From Bristol Myers Squibb
Via Business Wire
Merck Nears Breakout Point After October Surprise Good News
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022
From Bristol Myers Squibb
Via Business Wire
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
From Autolus Therapeutics plc
Via GlobeNewswire
Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.